Eli Lilly (LLY) Expected to React Positively as Biogen's Lecanemab Hits - UBS
Tweet Send to a Friend
UBS analyst Colin Bristow reiterated a Buy rating and $363.00 price target on Eli Lilly (NYSE: LLY), saying he expects ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
